BHCM
DTIL icon

Brevan Howard Capital Management’s Precision BioSciences DTIL Stock Holding History

Brevan Howard Capital Management’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-34,442
Closed -$189K – 2183
2026
Q1 		$189K Buy
+34,442
New +$159K ﹤0.01% 1913

Other funds holding DTIL

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Brevan Howard Capital Management's DTIL Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Precision BioSciences (DTIL) in Q2 2026, closing a stake of 34,442 shares — an estimated $189K sold.

Brevan Howard Capital Management first reported a position in DTIL in Q1 2026 and held it in 1 quarter. The position peaked at $189K in Q1 2026. 95 funds tracked by Wall St. Rank hold DTIL as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Precision BioSciences position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 34,442 Precision BioSciences shares in Q2 2026, an estimated $189K.
  • Brevan Howard Capital Management first reported a position in Precision BioSciences in Q1 2026 and held it in 1 quarter.
  • Brevan Howard Capital Management's Precision BioSciences position peaked at $189K in Q1 2026.
  • 95 funds tracked by Wall St. Rank held Precision BioSciences as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.